Immunome (NASDAQ: IMNM) CSO gifts 6,291 shares, retains 31,438

Rhea-AI Filing Summary

Immunome Inc. Chief Scientific Officer Jack Higgins reported a bona fide gift of 6,291 shares of Common Stock. The gift, coded as a disposition, carried a price of $0.00 per share. Following this transfer, he directly holds 31,438 shares of Immunome Common Stock.

The filing also lists indirect holdings of 1,000 shares of Common Stock in each of three custodial accounts for his children, recorded under the Uniform Transfer to Minors Act. Higgins disclaims beneficial ownership of these custodial shares, which are subject to a lockup agreement he entered into on December 15, 2025.

Insider Trade Summary

6,291 shares gifted

Mixed 4 txns

Insider Higgins Jack

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Gift	Common Stock	6,291	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 31,438 shares (Direct); Common Stock — 1,000 shares (Indirect, As Custodian for Child 1)

Footnotes (1)

1. [object Object]

Key Figures

Gifted shares: 6,291 shares Direct holdings after gift: 31,438 shares Custodial holdings per child: 1,000 shares +3 more

6 metrics

Gifted shares 6,291 shares Bona fide gift of Common Stock on March 30, 2026

Direct holdings after gift 31,438 shares Common Stock directly held following the reported gift

Custodial holdings per child 1,000 shares Indirect Common Stock holdings in each of three child custodial accounts

Total custodial holdings 3,000 shares Sum of three 1,000-share custodial accounts for children

Gift transactions 1 transaction Form 4 transactionSummary shows one bona fide gift

Gifted share price $0.00 per share Reported transaction price for gifted Common Stock

Key Terms

bona fide gift, Uniform Transfer to Minors Act, beneficial ownership, lockup agreement, +1 more

5 terms

bona fide gift financial

"The transaction_code_description identifies the disposition as a "Bona fide gift"."

Uniform Transfer to Minors Act regulatory

"A custodial account for his child pursuant to the Uniform Transfer to Minors Act."

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of these shares."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

lockup agreement financial

"The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025."

Section 16 regulatory

"Not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16."

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Higgins Jack

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/30/2026		G		6,291	D	$0	31,438	D
Common Stock								1,000(1)	I	As Custodian for Child 1
Common Stock								1,000(1)	I	As Custodian for Child 2
Common Stock								1,000(1)	I	As Custodian for Child 3

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025.

	/s/ Sandra Stoneman, Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Immunome (IMNM) report for Jack Higgins?

Immunome Chief Scientific Officer Jack Higgins reported a bona fide gift of 6,291 shares of Common Stock. The gift was recorded at $0.00 per share and left him with 31,438 directly held shares afterward.

How many Immunome (IMNM) shares does Jack Higgins hold after the gift?

After the 6,291-share gift, Jack Higgins directly holds 31,438 shares of Immunome Common Stock. The Form 4 also lists three custodial accounts of 1,000 shares each, which he reports indirectly and disclaims beneficial ownership.

Are Jack Higgins’ children’s Immunome (IMNM) shares included in his beneficial ownership?

The filing shows 1,000 Immunome shares in each of three custodial accounts for his children under the Uniform Transfer to Minors Act. Higgins expressly disclaims beneficial ownership of these shares for Section 16 and any other purpose.

What does the bona fide gift code mean in the Immunome (IMNM) Form 4?

The transaction is coded as a bona fide gift, indicating a gratuitous transfer of 6,291 shares with no sale proceeds. Such gifts are dispositions but are not market sales, so they do not reflect open-market trading activity by the insider.

Are any of Jack Higgins’ Immunome (IMNM) shares subject to a lockup agreement?

Yes. The footnote states the custodial shares for his children are subject to a lockup agreement he entered on December 15, 2025. This agreement limits transfers of those particular shares during the lockup period described.